4.6 Article

Upregulation of long noncoding RNA TUG1 promotes cervical cancer cell proliferation and migration

期刊

CANCER MEDICINE
卷 6, 期 2, 页码 471-482

出版社

WILEY
DOI: 10.1002/cam4.994

关键词

Bcl-2; cervical cancer; epithelial-mesenchymal1 transition; LncRNA; TUG1

类别

资金

  1. National Nature Science Foundation of China [81472308, 81672707]
  2. Zhejiang Provincial Natural Science Foundation of China [LQ15C010002, LY14H190003]
  3. Scientific Research Foundation of Wenzhou [Y20100175]
  4. Zhejiang Provincial Medical and Health Science and Technology plan [2013RCA035]
  5. Project of Science and Technology Department of Zhejiang Province [2014C37003]

向作者/读者索取更多资源

Long noncoding RNAs (lncRNAs), a novel class of transcripts that have critical roles in carcinogenesis and progression, have emerged as important gene expression modulators. Recent evidence indicates that lncRNA taurine-upregulated gene 1 (TUG1) functions as an oncogene in numerous types of human cancers. However, its function in the development of cervical cancer remains unknown. The aim of this research was to investigate the clinical significance and biological functions of TUG1 in cervical cancer. TUG1 was found to be significantly upregulated in cervical cancer tissues and four cervical cancer cell lines by quantitative real-time polymerase chain reaction (qRT-PCR). Elevated TUG1 expression was correlated with larger tumor size, advanced international federation of gynecology and obstetrics (FIGO) stage, poor differentiation, and lymph node metastasis. Furthermore, knockdown of TUG1 suppressed cell proliferation with activation of apoptosis, in part by regulating the expression of Bcl-2 and caspase-3. Silencing of TUG1 inhibited cell migration and invasion via the progression of epithelial-mesenchymal transition (EMT). Taken together, our findings indicate that TUG1 acts as an oncogene in cervical cancer and may represent a novel therapeutic target.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据